These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 9556058)

  • 41. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
    Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank MA; Phipps RJ; Rogers MJ
    Bone; 2001 Oct; 29(4):336-43. PubMed ID: 11595616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
    Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
    Nishiguchi T; Akiyoshi T; Anami S; Nakabayashi T; Matsuyama K; Matzno S
    J Pharm Pharmacol; 2009 Jun; 61(6):781-8. PubMed ID: 19505369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
    Rogers MJ; Mönkkönen J; Munoz MA
    Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
    van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
    Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
    Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
    J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
    Van Beek ER; Löwik CW; Papapoulos SE
    Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
    Woo JT; Kasai S; Stern PH; Nagai K
    J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanism of action of bisphosphonates.
    Reszka AA; Rodan GA
    Curr Osteoporos Rep; 2003 Sep; 1(2):45-52. PubMed ID: 16036064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-cancer therapy: targeting the mevalonate pathway.
    Swanson KM; Hohl RJ
    Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.
    Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
    J Biomed Sci; 2014 Feb; 21(1):10. PubMed ID: 24490900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
    J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis.
    Green JR; Clézardin P
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S3-9. PubMed ID: 12562045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.